PATENT CLAIM ANALYSIS

Application Number: 15769793
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["514", "323000"]

Abstract:
It is an object of the present invention to provide a novel therapeutic agent and method for treating amyotrophic diseases, and more specifically a therapeutic agent and method for treating neurogenic amyotrophic disorders such as amyotrophic lateral sclerosis (ALS) and myogenic amyotrophic disorders such as sarcopenia or disuse muscle atrophy. Provided is a therapeutic agent for amyotrophic diseases that comprises one or more compounds selected from the group consisting of compounds represented by the formula (I), the formula (II) and the formula (III), and pharmaceutically acceptable salts of the compounds when R 3  represents OH.

Claim (Index 9):
The method according to  claim 7 , wherein the myogenic amyotrophic disease is progressive muscular dystrophy, myotonic dystrophy, congenital myopathy, metabolic myopathy, distal myopathy, inflammatory myopathy, age-related muscle atrophy (sarcopenia), Barth syndrome or disuse muscle atrophy.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 95.0
- Lexical Diversity: 1.74194
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14646640', '16017520', '15873571', '15429738', '15318735']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.777881510884972
- 35 USC 102 Novelty (BERT): 0.5168999978770116
- Combined Prediction Score: 0.751783359584176
- Mean Citation Score: 249.208048
- Max Citation Score: 301.81195
- Similarity Product: 219.5623895268977

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test